Pfizer Inc. (NYSE:PFE) Stock Holdings Lifted by America First Investment Advisors LLC

America First Investment Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE) by 0.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 653,444 shares of the biopharmaceutical company’s stock after acquiring an additional 3,190 shares during the quarter. Pfizer makes up about 3.8% of America First Investment Advisors LLC’s investment portfolio, making the stock its 17th largest holding. America First Investment Advisors LLC’s holdings in Pfizer were worth $17,336,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer during the 4th quarter valued at $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

Pfizer Stock Down 2.2 %

Shares of PFE opened at $25.56 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50-day simple moving average of $26.14 and a 200-day simple moving average of $27.00. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a market capitalization of $144.96 billion, a P/E ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.